NXNN Stock Overview
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Nexeon Medsystems Inc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$0.0001 |
52 Week Low | US$0.0001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -99.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
NXNN | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | -0.2% | 0.6% |
1Y | n/a | 12.0% | 29.5% |
Return vs Industry: Insufficient data to determine how NXNN performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how NXNN performed against the US Market.
Price Volatility
NXNN volatility | |
---|---|
NXNN Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NXNN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NXNN's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Will Rosellini | https://www.nexeonmedsystems.com |
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson’s disease in the United States, as well as for Parkinson’s disease, Essential Tremor, and Dystonia in Europe.
Nexeon Medsystems Inc Fundamentals Summary
NXNN fundamental statistics | |
---|---|
Market cap | US$203.00 |
Earnings (TTM) | -US$1.65m |
Revenue (TTM) | US$9.82m |
0.0x
P/S Ratio0.0x
P/E RatioIs NXNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NXNN income statement (TTM) | |
---|---|
Revenue | US$9.82m |
Cost of Revenue | US$7.12m |
Gross Profit | US$2.71m |
Other Expenses | US$4.36m |
Earnings | -US$1.65m |
Last Reported Earnings
Sep 30, 2018
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did NXNN perform over the long term?
See historical performance and comparison